Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)

Summary

Seeking Alpha Healthcare initiates a Buy rating on Silence Therapeutics, suggesting that pharmacovigilance data could be a positive catalyst for the stock. The article title indicates expectations around data readout, though specific trial details are not provided in the headline.